Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06164275 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

A Phase 2 study of Classic Hodgkin Lymphoma, sponsored by Northwestern University.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
4
Study locations

NCT06164275: Active Phase 2 study of Classic Hodgkin Lymphoma, sponsored by Northwestern University.

NCT06164275 is a Phase 2 study of Classic Hodgkin Lymphoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 30 participants, below the 249-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06164275, a Phase 2 study of Classic Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb)" that uses the body's immune system to help fight and kill cancer cells. Chemotherapy drugs, such as doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Giving pembrolizumab followed by chemotherapy may work to treat patients with classical Hodgkin lymphoma.

Primary Outcome

Assessed by position emission tomography (PET)-computed tomography (CT). CR defined as 1-3 on the five-point scale per Lugano (Lugano 2014 Response Criteria). Patients with 1-3 per Deauville criteria will be considered a complete response. Response will be determined, using a proportion and an exact binomial 95% confidence interval.

Conditions Studied

Classic Hodgkin Lymphoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • DRUG Doxorubicin
  • DRUG Dacarbazine

Study Locations (4)

Illinois

  • Northwestern University - Chicago
  • Northwestern Delnor IL258 - Geneva
  • Cadence Health - CDH - Warrenville

California

  • Stanford Cancer Center - Stanford

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-02-06
Est. Completion 2031-12-31
Phase Phase 2
Northwestern University

1,209 total trials

What the registry record for NCT06164275 still lists

NCT06164275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 249-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06164275 reports a single indexed study location in Illinois, California.

Frequently Asked Questions

What is clinical trial NCT06164275 about?

NCT06164275 is a clinical study titled "Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma". This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb)" that uses the body's immune system to help figh...

What is the current status of trial NCT06164275?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-02-06. Estimated completion is 2031-12-31.

What conditions does trial NCT06164275 study?

This clinical trial studies the following conditions: Classic Hodgkin Lymphoma.

What interventions are being tested in trial NCT06164275?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Doxorubicin (DRUG), Dacarbazine (DRUG).

Who is sponsoring clinical trial NCT06164275?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06164275 being conducted?

This trial has 4 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Classic Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06164275's enrollment target sits among peer trials

30 8th of 9 higher than 2 of 9 other Classic Hodgkin Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Classic Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06164275, the US trial registry maintained by the National Library of Medicine. NCT06164275 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.